ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE

To provide a pharmaceutical composition for treating multiple myeloma.SOLUTION: In the pharmaceutical composition, a compound represented by the formula 1 in the figure, or an enantiomer, a mixture of enantiomers, a tautomer or a pharmaceutically acceptable salt thereof, is used in combination with...

Full description

Saved in:
Bibliographic Details
Main Authors DANIEL W PIERCE, LILLY L WONG
Format Patent
LanguageEnglish
Japanese
Published 22.08.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:To provide a pharmaceutical composition for treating multiple myeloma.SOLUTION: In the pharmaceutical composition, a compound represented by the formula 1 in the figure, or an enantiomer, a mixture of enantiomers, a tautomer or a pharmaceutically acceptable salt thereof, is used in combination with a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3ε (CD3).SELECTED DRAWING: Figure 4 【課題】多発性骨髄腫の治療のための医薬組成物を提供する。【解決手段】下式１で表される化合物、またはそのエナンチオマー、エナンチオマーの混合物、互変異性体、もしくは薬学的に許容される塩、ならびにヒトＢ細胞成熟抗原（ＢＣＭＡ）に特異的に結合する第１の結合部分及びヒトＣＤ３ε（ＣＤ３）に特異的に結合する第２の結合部分を含む二重特異性抗体、とを併用して使用する医薬組成物とする。TIFF2023116613000047.tif44170【選択図】図４
Bibliography:Application Number: JP20230093659